Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +50

Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout β€” What Investors Need to Know

AI-generated analysis

πŸ“… On April 28, 2026, Gilead Sciences finalized the $7.8 billion acquisition of Arcellx, securing full ownership of anito-cel.

πŸ’° The deal values Arcellx at roughly $7.8 billion, offering $115 cash per share plus a $5 contingent value right.

🧬 Anito-cel is an experimental BCMA-targeted CAR T-cell therapy designed to treat patients with multiple myeloma.

βš–οΈ This acquisition removes future royalty commitments and milestone payments, enabling more agile development timelines.

πŸ“‰ Gilead's stock (GILD) dropped 8% in April and has fallen 4% since January despite being up 22% year-over-year.

πŸ“ˆ Technical analysis indicates GILD is retesting an 11-year cup base breakout level at $123.47, with a projected upside target of $173 by year-end.

πŸ“‰ Financially, the deal will reduce GAAP and non-GAAP earnings per share by $5.57–$5.67 in 2026 due to accounting impacts.

πŸš€ Earnings accretion is projected to begin in 2028, contingent on receiving FDA authorization for anito-cel.

πŸ’° The contingent value right activates only if global sales of anito-cel reach $6 billion before December 31, 2029.

🀝 Personnel and the proprietary D-Domain BCMA binder platform from Arcellx will integrate into Gilead's Kite division.

πŸ“‰ The Relative Strength Index (RSI) for GILD has dropped to 27, marking its most oversold reading in over 12 months.

πŸ“‰ About 77.2% of Arcellx's outstanding equity was tendered during the completed acquisition process.

πŸ“ˆ Broader biotech ETFs are underperforming the healthcare sector, with GILD maintaining support near $118 as a key bullish indicator.

Bullish Signals
  • Gilead Sciences closed a $7.8 billion acquisition of Arcellx on April 28, securing complete ownership of anito-cel, an advanced CAR T-cell treatment for multiple myeloma.
  • Analysts project the stock could climb to $173 by December from current levels near $128, representing significant upside potential.
  • The stock is technically oversold with an RSI at 27, its lowest reading in over 12 months, suggesting a potential rebound opportunity.
  • Despite recent weakness, shares remain up 22% year-over-year and have advanced 4% since January 2026.
  • The acquisition removes future royalty commitments and milestone payments, enabling more agile decision-making for development and market launch strategies.
  • Management's $5 contingent value right per share demonstrates confidence in anito-cel generating cumulative worldwide sales of at least $6 billion by December 31, 2029.
  • Cindy Perettie, who leads Gilead's Kite division, emphasized the priority is executing with speed and discipline to prepare anito-cel for patient access.
  • The SPDR S&P Biotech ETF has climbed 9% in 2026, significantly outperforming the broader healthcare sector's decline.
  • Extended consolidation patterns historically demonstrate higher breakout success probabilities, making GILD's current technical position particularly significant.
  • Tendered shares accounted for approximately 77.2% of Arcellx's total outstanding equity, indicating strong investor participation in the acquisition.
Risk Factors
  • The $7.8 billion acquisition of Arcellx will immediately reduce Gilead's 2026 diluted earnings per share by $5.57 to $5.67 under both GAAP and adjusted metrics.
  • Full integration benefits from the anito-cel treatment are not expected until 2028, requiring nearly two years before the deal becomes accretive to earnings.
  • The acquisition's value is contingent on the FDA clearing anito-cel for multiple myeloma patients before any revenue contributions can begin.
  • A significant $5 billion revenue target must be achieved between launch and December 31, 2029 to trigger the remaining $5 per share contingent value right payment.
  • Gilead shares have dropped 8% during April, with losses posted in eight of the previous ten weeks despite lighter-than-average trading volume.
  • The SPDR S&P Biotech ETF has contributed positively to broader performance, yet GILD remains a significant component of the iShares Biotechnology ETF which is underperforming with less than 1% returns year-to-date.
Full Analysis
On April 28, 2026, Gilead Sciences finalized its $7.8 billion purchase of Arcellx, completing a tender offer in which approximately 77.2% of Arcellx's total outstanding equity was accepted at $115 per share plus a $5 contingent value right. The transaction grants Gilead complete ownership of anito-cel, an experimental BCMA-targeted CAR T-cell treatment for multiple myeloma developed through their previous partnership with Kite. By acquiring full control, Gilead eliminates future royalty commitments and milestone payments, allowing for more agile decision-making regarding the therapy's development timelines and market launch strategies. Arcellx's personnel and proprietary D-Domain BCMA binder platform will integrate into Kite's existing manufacturing and compliance frameworks, while shares of Arcellx will be removed from Nasdaq Global Select Market trading upon merger conclusion. The acquisition carries specific financial implications for Gilead, projected to reduce both GAAP and non-GAAP diluted earnings per share by $5.57 to $5.67 in 2026. While the deal creates a temporary drag on earnings, projections indicate that anito-cel will begin contributing positively to earnings in 2028, contingent upon regulatory clearance from the FDA. The company's management has emphasized executing with speed and discipline to prepare anito-cel for patient access. A key component of the deal structure is the $5 per share CVR payment, which will only trigger if anito-cel achieves cumulative worldwide sales reaching $6 billion between its launch date and December 31, 2029. This threshold reflects Gilead's optimism regarding the therapy's revenue potential despite the significant challenge to meet the sales target. From a technical analysis perspective, Gilead Sciences (GILD) stock is currently retesting breakout levels near $123.47, originating from an 11-year cup base formation established in June and July 2015. The stock dropped 8% during April but remains up 22% year-over-year, trading near $128 as of the article's writing with a Relative Strength Index of 27, its most oversold reading in over 12 months. Analysts note that GILD has posted losses in eight of the previous ten weeks, yet volume remained lighter than average during March and April decline periods, which technical traders often interpret as a positive divergence. With the 200-day moving average providing nearby support, one market watcher projects the stock could climb to $173 by December, representing potential upside of 35%, provided shares maintain support above $118.